1. Kumar A*, Chamoto K* (*equally contributed), Chowdhury PS, Honjo T. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy. (2020) Elife. 9, pii: e52330.
2. Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. (2020) Int J Clin Oncol., 25:790-800.
3. Yanagihara T*, Tanaka K* (*equally contributed), Matsumoto K*. A measuring method for occupancy of immune checkpoint inhibitors in the cell surface. (2020) Biochemical and Biophysical Research Communications 527(1), 213-217.
4. Kato R, Hayashi H, Chiba Y, Miyawaki E, Shimizu J, Ozaki T, Fujimoto D, Toyozawa R, Nakamura A, Kozuki T, Tanaka K, Teraoka S, Usui K, Nishino K, Hataji O, Ota K, Ebi N, Saeki S, Akazawa Y, Okuno M, Yamamoto N, Nakagawa K. Propensity Score-Weighted Analysis of Chemotherapy After PD-1 Inhibitors Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Cancer (WJOG10217L) (2020) Journal for ImmunoTherapy of Cancer. 8(1): e000350.
5. Morita R, Okishio K, Shimizu J, Saito H, Sakai H, Kim YH, Hataji O, Yomota M, Nishio M, Aoe K, Kanai O, Kumagai T, Kibata K, Tsukamoto H, Oizumi S, Fujimoto D, Tanaka H, Mizuno K, Masuda T, Kozuki T, Haku T, Suzuki H, Okamoto I, Hoshiyama H, Ueda J, Ohe Y. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. (2020) Lung Cancer. 140:8-18.
6. Hatae R*, Chamoto K* (*equally contributed), Kim YH, Sonomura K, Taneishi K, Kawaguchi S, Yoshida H, Ozasa H, Sakamori Y, Akrami M, Fagarasan S, Masuda I, Okuno Y, Matsuda F, Hirai T, Honjo H. Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy (2019) JCI insight, 5, pii: 133501.
7. Ikematsu Y, Tanaka K* (*corresponding author), Yanagihara T, Liu R, Inoue H, Yoneshima Y, Ota K, Iwama E, Takata S, Hata K, Takahata Y, Wataya H, Nakanishi Y, Okamoto I. Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. (2019) Lung Cancer, 138, 58-64.
8. Yoneshima Y, Tanaka K, Shiraishi Y, Hata K, Watanabe H, Harada T, Otsubo K, Iwama E, Inoue H, Masuda S, Nakanishi Y, Okamoto I * (*corresponding author). Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies. (2019) Lung Cancer 130:5-9.
9. Takada K, Toyokawa G, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Haro A, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M. 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. (2019) Scientific Reports 9:13362.